Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-06-12

AUTHORS

Joan Carles, Isabel Chirivella, Miguel Ángel Climent, Enrique Gallardo, Arancha González del Alba, José Pablo Maroto, Begoña Mellado, Francisco Xavier García del Muro

ABSTRACT

The approval and use of molecular targeted agents for the first-line treatment of metastatic renal cell carcinoma (mRCC) has substantially improved the clinical outcome of patients. Although eventually all patients progress, hopes have been renewed with the approval of everolimus for patients who progress on or after treatment with tyrosine kinase inhibitors. In order to improve the prognosis for these patients, it is imperative to understand the reasons why patients with mRCC fail on first-line treatment. Currently, progression is assessed on the basis of the Response Evaluation Criteria in Solid Tumors, but it is known that targeted agents tend to cause disease stabilization rather than a significant decrease in tumor mass. Therefore, it may be time to evaluate the need to incorporate additional diagnostic methods in the assessment of disease response. Equally important is the study of the factors that determine the success or failure of second-line therapy in order to increase the chances of delivering the most effective and personalized therapy possible. In this article, we review the evidence related to the evaluation of patients with mRCC who fail on first-line treatment with targeted agents, including the systems to assess response and progression, the prognostic factors, the prognostic models that have been created based on these factors, and what is known about predictive biomarkers of disease outcome. More... »

PAGES

3-9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0

DOI

http://dx.doi.org/10.1007/s10555-012-9353-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013240949

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22689342


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Service, Hospital Universitari Vall d\u2019Hebron, Passeig de la Vall d\u2019Hebron, 119-129, 08035, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Medical Oncology Service, Hospital Universitari Vall d\u2019Hebron, Passeig de la Vall d\u2019Hebron, 119-129, 08035, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carles", 
        "givenName": "Joan", 
        "id": "sg:person.0633222263.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633222263.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411308.f", 
          "name": [
            "Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chirivella", 
        "givenName": "Isabel", 
        "id": "sg:person.01322202424.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322202424.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda, Valencia, Spain", 
          "id": "http://www.grid.ac/institutes/grid.418082.7", 
          "name": [
            "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda, Valencia, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Climent", 
        "givenName": "Miguel \u00c1ngel", 
        "id": "sg:person.01305201047.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305201047.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed, l\u2019Hospital de Sabadell, Sabadell, Spain", 
          "id": "http://www.grid.ac/institutes/grid.428313.f", 
          "name": [
            "Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed, l\u2019Hospital de Sabadell, Sabadell, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gallardo", 
        "givenName": "Enrique", 
        "id": "sg:person.01264637747.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264637747.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitari Son Dureta, Palma de Mallorca, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411161.2", 
          "name": [
            "Hospital Universitari Son Dureta, Palma de Mallorca, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gonz\u00e1lez del Alba", 
        "givenName": "Arancha", 
        "id": "sg:person.01221412261.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221412261.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital de la Santa Creu i Sant Pau, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.413396.a", 
          "name": [
            "Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maroto", 
        "givenName": "Jos\u00e9 Pablo", 
        "id": "sg:person.01301016555.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301016555.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Clinic de Barcelona, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.410458.c", 
          "name": [
            "Hospital Clinic de Barcelona, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mellado", 
        "givenName": "Bego\u00f1a", 
        "id": "sg:person.01234274675.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234274675.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Catal\u00e0 d\u2019Oncolog\u00eda, Hospital Duran i Reynals, l\u2019Hospitalet de Llobregat, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Institut Catal\u00e0 d\u2019Oncolog\u00eda, Hospital Duran i Reynals, l\u2019Hospitalet de Llobregat, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garc\u00eda del Muro", 
        "givenName": "Francisco Xavier", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11523-010-0146-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030648477", 
          "https://doi.org/10.1007/s11523-010-0146-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-008-0018-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032981147", 
          "https://doi.org/10.1007/s10549-008-0018-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-06-12", 
    "datePublishedReg": "2012-06-12", 
    "description": "The approval and use of molecular targeted agents for the first-line treatment of metastatic renal cell carcinoma (mRCC) has substantially improved the clinical outcome of patients. Although eventually all patients progress, hopes have been renewed with the approval of everolimus for patients who progress on or after treatment with tyrosine kinase inhibitors. In order to improve the prognosis for these patients, it is imperative to understand the reasons why patients with mRCC fail on first-line treatment. Currently, progression is assessed on the basis of the Response Evaluation Criteria in Solid Tumors, but it is known that targeted agents tend to cause disease stabilization rather than a significant decrease in tumor mass. Therefore, it may be time to evaluate the need to incorporate additional diagnostic methods in the assessment of disease response. Equally important is the study of the factors that determine the success or failure of second-line therapy in order to increase the chances of delivering the most effective and personalized therapy possible. In this article, we review the evidence related to the evaluation of patients with mRCC who fail on first-line treatment with targeted agents, including the systems to assess response and progression, the prognostic factors, the prognostic models that have been created based on these factors, and what is known about predictive biomarkers of disease outcome.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10555-012-9353-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096239", 
        "issn": [
          "0167-7659", 
          "1573-7233"
        ], 
        "name": "Cancer and Metastasis Reviews", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "first-line treatment", 
      "evaluation of patients", 
      "renal cell carcinoma", 
      "cell carcinoma", 
      "second-line therapy", 
      "approval of everolimus", 
      "Response Evaluation Criteria", 
      "tyrosine kinase inhibitors", 
      "additional diagnostic methods", 
      "disease stabilization", 
      "prognostic factors", 
      "clinical outcomes", 
      "targeted agents", 
      "predictive biomarkers", 
      "disease outcome", 
      "tumor mass", 
      "patients", 
      "solid tumors", 
      "prognostic model", 
      "personalized therapy", 
      "significant decrease", 
      "disease response", 
      "kinase inhibitors", 
      "treatment", 
      "carcinoma", 
      "diagnostic methods", 
      "therapy", 
      "progression", 
      "outcomes", 
      "approval", 
      "agents", 
      "failure", 
      "everolimus", 
      "prognosis", 
      "tumors", 
      "factors", 
      "response", 
      "biomarkers", 
      "evaluation", 
      "inhibitors", 
      "evaluation criteria", 
      "assessment", 
      "evidence", 
      "decrease", 
      "criteria", 
      "study", 
      "chance", 
      "use", 
      "hope", 
      "need", 
      "mass", 
      "reasons", 
      "success", 
      "time", 
      "stabilization", 
      "basis", 
      "article", 
      "method", 
      "model", 
      "order", 
      "system"
    ], 
    "name": "Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment", 
    "pagination": "3-9", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013240949"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10555-012-9353-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22689342"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10555-012-9353-0", 
      "https://app.dimensions.ai/details/publication/pub.1013240949"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_561.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10555-012-9353-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0'


 

This table displays all metadata directly associated to this object as RDF triples.

225 TRIPLES      22 PREDICATES      95 URIs      85 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10555-012-9353-0 schema:about N0723b4430c5b40c5802a1acc4dd0d476
2 N181418ef08774683b138f0881e0956ce
3 N81769907b205468b80213f6cf18c3ddd
4 Nc4af3b07e4d443b0913d50afda17f271
5 Ne0b9894606ad429da61751f2ca66190c
6 Nf5d1fa2c24724e43a1110b418c5d9fd7
7 anzsrc-for:11
8 anzsrc-for:1103
9 schema:author N27357dd79bd44f5ab467f8efeb8194dd
10 schema:citation sg:pub.10.1007/s10549-008-0018-1
11 sg:pub.10.1007/s11523-010-0146-5
12 schema:datePublished 2012-06-12
13 schema:datePublishedReg 2012-06-12
14 schema:description The approval and use of molecular targeted agents for the first-line treatment of metastatic renal cell carcinoma (mRCC) has substantially improved the clinical outcome of patients. Although eventually all patients progress, hopes have been renewed with the approval of everolimus for patients who progress on or after treatment with tyrosine kinase inhibitors. In order to improve the prognosis for these patients, it is imperative to understand the reasons why patients with mRCC fail on first-line treatment. Currently, progression is assessed on the basis of the Response Evaluation Criteria in Solid Tumors, but it is known that targeted agents tend to cause disease stabilization rather than a significant decrease in tumor mass. Therefore, it may be time to evaluate the need to incorporate additional diagnostic methods in the assessment of disease response. Equally important is the study of the factors that determine the success or failure of second-line therapy in order to increase the chances of delivering the most effective and personalized therapy possible. In this article, we review the evidence related to the evaluation of patients with mRCC who fail on first-line treatment with targeted agents, including the systems to assess response and progression, the prognostic factors, the prognostic models that have been created based on these factors, and what is known about predictive biomarkers of disease outcome.
15 schema:genre article
16 schema:inLanguage en
17 schema:isAccessibleForFree false
18 schema:isPartOf N40fece15a8b748f6826c6e4c83712391
19 N41654093639c43e99476048c8b47d675
20 sg:journal.1096239
21 schema:keywords Response Evaluation Criteria
22 additional diagnostic methods
23 agents
24 approval
25 approval of everolimus
26 article
27 assessment
28 basis
29 biomarkers
30 carcinoma
31 cell carcinoma
32 chance
33 clinical outcomes
34 criteria
35 decrease
36 diagnostic methods
37 disease outcome
38 disease response
39 disease stabilization
40 evaluation
41 evaluation criteria
42 evaluation of patients
43 everolimus
44 evidence
45 factors
46 failure
47 first-line treatment
48 hope
49 inhibitors
50 kinase inhibitors
51 mass
52 metastatic renal cell carcinoma
53 method
54 model
55 need
56 order
57 outcomes
58 patients
59 personalized therapy
60 predictive biomarkers
61 prognosis
62 prognostic factors
63 prognostic model
64 progression
65 reasons
66 renal cell carcinoma
67 response
68 second-line therapy
69 significant decrease
70 solid tumors
71 stabilization
72 study
73 success
74 system
75 targeted agents
76 therapy
77 time
78 treatment
79 tumor mass
80 tumors
81 tyrosine kinase inhibitors
82 use
83 schema:name Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
84 schema:pagination 3-9
85 schema:productId N6d47185a5a6d40e3ad369c3073d3f68a
86 N7e4fa4987f55488cbbb6e0b36692b983
87 Ne9e528faf9944dd8b706e46095791d21
88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013240949
89 https://doi.org/10.1007/s10555-012-9353-0
90 schema:sdDatePublished 2021-12-01T19:25
91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
92 schema:sdPublisher N2b44183a48df4b9ca068cfa0af63288b
93 schema:url https://doi.org/10.1007/s10555-012-9353-0
94 sgo:license sg:explorer/license/
95 sgo:sdDataset articles
96 rdf:type schema:ScholarlyArticle
97 N0723b4430c5b40c5802a1acc4dd0d476 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Carcinoma, Renal Cell
99 rdf:type schema:DefinedTerm
100 N181418ef08774683b138f0881e0956ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Neoplasm Metastasis
102 rdf:type schema:DefinedTerm
103 N25682826899544eba6f4d221e3c1afa8 rdf:first sg:person.01221412261.54
104 rdf:rest N34542f6b9a0a40a29b52c65092d1c305
105 N27357dd79bd44f5ab467f8efeb8194dd rdf:first sg:person.0633222263.47
106 rdf:rest Na9c932fd33af418baa33f8712cf1b6ba
107 N2b44183a48df4b9ca068cfa0af63288b schema:name Springer Nature - SN SciGraph project
108 rdf:type schema:Organization
109 N34542f6b9a0a40a29b52c65092d1c305 rdf:first sg:person.01301016555.42
110 rdf:rest Nb50fc831521b4235b6fe13a705cc4da6
111 N40fece15a8b748f6826c6e4c83712391 schema:issueNumber Suppl 1
112 rdf:type schema:PublicationIssue
113 N41654093639c43e99476048c8b47d675 schema:volumeNumber 31
114 rdf:type schema:PublicationVolume
115 N63bfe9f8504341408e0ae2487391dea1 schema:affiliation grid-institutes:None
116 schema:familyName García del Muro
117 schema:givenName Francisco Xavier
118 rdf:type schema:Person
119 N6953e61f8f34481c847788bab07d826d rdf:first N63bfe9f8504341408e0ae2487391dea1
120 rdf:rest rdf:nil
121 N6d47185a5a6d40e3ad369c3073d3f68a schema:name pubmed_id
122 schema:value 22689342
123 rdf:type schema:PropertyValue
124 N7e4fa4987f55488cbbb6e0b36692b983 schema:name doi
125 schema:value 10.1007/s10555-012-9353-0
126 rdf:type schema:PropertyValue
127 N81769907b205468b80213f6cf18c3ddd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Kidney Neoplasms
129 rdf:type schema:DefinedTerm
130 Na10fbb0e994545998fdf68298e06ae68 rdf:first sg:person.01264637747.43
131 rdf:rest N25682826899544eba6f4d221e3c1afa8
132 Na9c932fd33af418baa33f8712cf1b6ba rdf:first sg:person.01322202424.66
133 rdf:rest Nd7ff959fa8354a79b3a639ddfe5fa3fa
134 Nb50fc831521b4235b6fe13a705cc4da6 rdf:first sg:person.01234274675.99
135 rdf:rest N6953e61f8f34481c847788bab07d826d
136 Nc4af3b07e4d443b0913d50afda17f271 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Prognosis
138 rdf:type schema:DefinedTerm
139 Nd7ff959fa8354a79b3a639ddfe5fa3fa rdf:first sg:person.01305201047.47
140 rdf:rest Na10fbb0e994545998fdf68298e06ae68
141 Ne0b9894606ad429da61751f2ca66190c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 Ne9e528faf9944dd8b706e46095791d21 schema:name dimensions_id
145 schema:value pub.1013240949
146 rdf:type schema:PropertyValue
147 Nf5d1fa2c24724e43a1110b418c5d9fd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Treatment Outcome
149 rdf:type schema:DefinedTerm
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
154 schema:name Clinical Sciences
155 rdf:type schema:DefinedTerm
156 sg:journal.1096239 schema:issn 0167-7659
157 1573-7233
158 schema:name Cancer and Metastasis Reviews
159 schema:publisher Springer Nature
160 rdf:type schema:Periodical
161 sg:person.01221412261.54 schema:affiliation grid-institutes:grid.411161.2
162 schema:familyName González del Alba
163 schema:givenName Arancha
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221412261.54
165 rdf:type schema:Person
166 sg:person.01234274675.99 schema:affiliation grid-institutes:grid.410458.c
167 schema:familyName Mellado
168 schema:givenName Begoña
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234274675.99
170 rdf:type schema:Person
171 sg:person.01264637747.43 schema:affiliation grid-institutes:grid.428313.f
172 schema:familyName Gallardo
173 schema:givenName Enrique
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264637747.43
175 rdf:type schema:Person
176 sg:person.01301016555.42 schema:affiliation grid-institutes:grid.413396.a
177 schema:familyName Maroto
178 schema:givenName José Pablo
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301016555.42
180 rdf:type schema:Person
181 sg:person.01305201047.47 schema:affiliation grid-institutes:grid.418082.7
182 schema:familyName Climent
183 schema:givenName Miguel Ángel
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305201047.47
185 rdf:type schema:Person
186 sg:person.01322202424.66 schema:affiliation grid-institutes:grid.411308.f
187 schema:familyName Chirivella
188 schema:givenName Isabel
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322202424.66
190 rdf:type schema:Person
191 sg:person.0633222263.47 schema:affiliation grid-institutes:grid.411083.f
192 schema:familyName Carles
193 schema:givenName Joan
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633222263.47
195 rdf:type schema:Person
196 sg:pub.10.1007/s10549-008-0018-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032981147
197 https://doi.org/10.1007/s10549-008-0018-1
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s11523-010-0146-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030648477
200 https://doi.org/10.1007/s11523-010-0146-5
201 rdf:type schema:CreativeWork
202 grid-institutes:None schema:alternateName Institut Català d’Oncología, Hospital Duran i Reynals, l’Hospitalet de Llobregat, Barcelona, Spain
203 schema:name Institut Català d’Oncología, Hospital Duran i Reynals, l’Hospitalet de Llobregat, Barcelona, Spain
204 rdf:type schema:Organization
205 grid-institutes:grid.410458.c schema:alternateName Hospital Clinic de Barcelona, Barcelona, Spain
206 schema:name Hospital Clinic de Barcelona, Barcelona, Spain
207 rdf:type schema:Organization
208 grid-institutes:grid.411083.f schema:alternateName Medical Oncology Service, Hospital Universitari Vall d’Hebron, Passeig de la Vall d’Hebron, 119-129, 08035, Barcelona, Spain
209 schema:name Medical Oncology Service, Hospital Universitari Vall d’Hebron, Passeig de la Vall d’Hebron, 119-129, 08035, Barcelona, Spain
210 rdf:type schema:Organization
211 grid-institutes:grid.411161.2 schema:alternateName Hospital Universitari Son Dureta, Palma de Mallorca, Spain
212 schema:name Hospital Universitari Son Dureta, Palma de Mallorca, Spain
213 rdf:type schema:Organization
214 grid-institutes:grid.411308.f schema:alternateName Hospital Clínico Universitario de Valencia, Valencia, Spain
215 schema:name Hospital Clínico Universitario de Valencia, Valencia, Spain
216 rdf:type schema:Organization
217 grid-institutes:grid.413396.a schema:alternateName Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
218 schema:name Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
219 rdf:type schema:Organization
220 grid-institutes:grid.418082.7 schema:alternateName Fundación Instituto Valenciano de Oncología, Valencia, Spain
221 schema:name Fundación Instituto Valenciano de Oncología, Valencia, Spain
222 rdf:type schema:Organization
223 grid-institutes:grid.428313.f schema:alternateName Corporació Sanitària Parc Taulí, l’Hospital de Sabadell, Sabadell, Spain
224 schema:name Corporació Sanitària Parc Taulí, l’Hospital de Sabadell, Sabadell, Spain
225 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...